// App-Quantinova.ai

P-107 : LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment

Researchers

Presenter

  • S. Ogasawara

Principal Investigators

  • J. Llovet

  • A. El-Khoueiry

  • A. Vogel

  • D. Madoff

  • R. Finn

  • Z. Ren

  • K. Modi

  • J. Li

  • A. Siegel

  • L. Dubrovsky

  • M. Kudo

Medical Centers

  • Graduate School of Medicine, Chiba University, Chiba, Japan

  • Icahn School of Medicine at Mount Sinai, Jamaica, NY, United States

  • Norris Comprehensive Cancer Center,Los Angeles,United States

  • Hannover Medical School, Hannover, Germany

  • Yale School of Medicine, Yale Cancer Center, and Yale New Haven Health, Smilow Cancer Hospital, New Haven, CT

  • Rheumatology, David Geffen School of Medicine, Los Angeles, United States

  • Huashan Hospital, Fudan University, Shanghai, China

  • Eisai, Inc Woodcliff Lake NJ United States

  • Merck & Co., Inc., Kenilworth, NJ, United States,

  • Kinki University Faculty of Medicine, Osaka, Japan

Locations

  • Japan

  • United States

  • Germany

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • Programmed cell death 1 ligand 2

  • Programmed death-ligand 1

  • Cytotoxic T-lymphocyte-associated protein 4

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved